NIH awards $135M+ contract for clinical site monitoring, with over 2,500 days of performance

Contract Overview

Contract Amount: $135,144,719 ($135.1M)

Contractor: PPD Development LP

Awarding Agency: Department of Health and Human Services

Start Date: 2017-01-31

End Date: 2024-01-31

Contract Duration: 2,556 days

Daily Burn Rate: $52.9K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 4

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: IGF::OT::IGF NIAID CLINICAL SITE MONITORING

Place of Performance

Location: WILMINGTON, NEW HANOVER County, NORTH CAROLINA, 28401

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $135.1 million to PPD DEVELOPMENT LP for work described as: IGF::OT::IGF NIAID CLINICAL SITE MONITORING Key points: 1. Contract value exceeds $135 million, indicating significant investment in research support services. 2. The contract spans over 2,500 days, suggesting a long-term need for consistent monitoring. 3. Awarded to PPD Development LP, a contractor with a substantial role in federal research. 4. The contract type is Cost Plus Fixed Fee, which allows for cost reimbursement plus a fixed fee. 5. Competition was full and open, implying a broad search for qualified bidders. 6. The North American Industry Classification System (NAICS) code 541712 points to R&D in physical, engineering, and life sciences. 7. This contract supports the National Institutes of Health (NIH) mission in biomedical research.

Value Assessment

Rating: good

The contract's total value of over $135 million for clinical site monitoring over approximately seven years suggests a substantial investment. Benchmarking this against similar large-scale clinical research support contracts is difficult without more specific service details. However, the Cost Plus Fixed Fee (CPFF) structure implies that costs are reimbursed, plus a negotiated fixed fee, which can offer a balance between contractor incentive and cost control. The fixed fee component, if well-negotiated, can represent good value, but the overall cost-effectiveness depends heavily on the efficiency and effectiveness of the services provided by PPD Development LP.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that all responsible sources were permitted to submit a bid. The presence of four bidders (no) suggests a competitive environment, though the exact number of bids received is not specified. Full and open competition generally promotes price discovery and allows the government to select the best value offering from a wide pool of potential contractors. This approach is intended to ensure fair pricing and access to a broad range of capabilities.

Taxpayer Impact: Taxpayers benefit from full and open competition through potentially lower prices and access to a wider array of innovative solutions. It ensures that the government is not limited to a single provider, fostering a market that drives efficiency and cost savings.

Public Impact

The primary beneficiaries are the research programs funded by the National Institutes of Health (NIH), which rely on effective clinical site monitoring to ensure data integrity and regulatory compliance. Services delivered include monitoring clinical trial sites to ensure adherence to protocols, good clinical practices, and regulatory requirements. The geographic impact is likely nationwide, supporting various research institutions and clinical sites across the United States where NIH-funded studies are conducted. Workforce implications include employment opportunities for clinical research associates, project managers, and other support staff within PPD Development LP and potentially at the monitored clinical sites.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

The Cost Plus Fixed Fee (CPFF) contract type can incentivize contractors to incur costs, as they are reimbursed, though the fixed fee aims to cap profit.
Long contract duration (2556 days) may lead to potential scope creep or evolving needs that could impact overall cost if not managed proactively.
Reliance on a single contractor for a significant duration requires robust oversight to ensure continued performance and value.

Positive Signals

Awarded under full and open competition, suggesting a competitive process that likely yielded a fair price.
The contractor, PPD Development LP, is a known entity in clinical research, implying experience and established processes.
The contract's clear definition of services (clinical site monitoring) indicates a focused objective for the funding.

Sector Analysis

The contract falls within the Research and Development in the Physical, Engineering, and Life Sciences sector, specifically NAICS code 541712. This sector is critical for advancing scientific knowledge and developing new technologies and treatments. The global market for clinical research services is substantial, driven by pharmaceutical and biotechnology companies, as well as government health agencies like NIH. NIH's spending in this area supports its mission to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and prevent illness. Comparable spending benchmarks would typically involve analyzing other large-scale contracts for clinical trial management and monitoring services awarded by government health entities.

Small Business Impact

The data indicates that this contract was not set aside for small businesses (ss: false, sb: false). As a large contract awarded through full and open competition, it is likely that PPD Development LP, as the prime contractor, may engage small businesses as subcontractors. However, without specific subcontracting plans or data, the direct impact on the small business ecosystem is unclear. Large federal contracts often have subcontracting goals, but the extent to which these are met and benefit small businesses would require further investigation.

Oversight & Accountability

Oversight for this contract would primarily reside with the contracting agency, the National Institutes of Health (NIH), and potentially its Office of the Inspector General (OIG) if specific concerns arise. The Cost Plus Fixed Fee (CPFF) structure necessitates diligent financial oversight to ensure that costs claimed by the contractor are reasonable, allocable, and allowable. Performance monitoring by the government contracting officer and technical representatives is crucial to ensure the contractor meets the defined objectives and deliverables. Transparency is generally maintained through contract award databases and reporting requirements, though detailed operational oversight specifics are typically internal.

Related Government Programs

NIH Clinical Center
National Institute of Allergy and Infectious Diseases (NIAID) Research Support
Federal Clinical Trial Management Services
Biomedical Research Support Contracts
Life Sciences Research and Development Funding

Risk Flags

Potential for cost overruns inherent in CPFF contracts.
Need for stringent government oversight to manage contractor costs.
Ensuring consistent performance quality over a long contract duration.
Managing evolving research needs within the defined contract scope.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $135.1 million to PPD DEVELOPMENT LP. IGF::OT::IGF NIAID CLINICAL SITE MONITORING

Who is the contractor on this award?

The obligated recipient is PPD DEVELOPMENT LP.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $135.1 million.

What is the period of performance?

Start: 2017-01-31. End: 2024-01-31.

What is the historical spending pattern for clinical site monitoring services by the NIH?

Analyzing the historical spending patterns for clinical site monitoring by the NIH requires access to detailed procurement data over multiple fiscal years. While this specific contract represents a significant award of over $135 million, understanding the broader trend involves examining the total obligated amounts for similar services across various NIH institutes and centers. Factors influencing historical spending include the volume of clinical trials initiated, changes in regulatory requirements (e.g., FDA mandates), and shifts in research priorities. A comprehensive analysis would compare current spending levels to previous years, identify any major increases or decreases, and correlate these with programmatic expansions or contractions. It would also involve looking at the number and value of contracts awarded for these services, as well as the primary contractors receiving these funds. Without access to a comprehensive historical database, it's challenging to provide precise figures, but the sustained need for such services suggests a consistent and significant allocation of NIH resources.

How does the pricing structure (Cost Plus Fixed Fee) compare to other contract types for similar services?

The Cost Plus Fixed Fee (CPFF) contract type is common for research and development or complex services where the scope may evolve or is not precisely defined at the outset. In a CPFF contract, the government reimburses the contractor for allowable costs incurred and pays a fixed fee representing profit. This contrasts with Fixed-Price contracts, where the price is set regardless of the actual costs incurred, offering more cost certainty to the government but potentially higher risk for the contractor if costs escalate. Cost-Reimbursement contracts (like Cost Plus Incentive Fee or Cost Plus Award Fee) also involve reimbursing costs but may include variable fees tied to performance targets. For clinical site monitoring, CPFF can be advantageous when the exact number of sites, frequency of monitoring, or specific challenges are not fully predictable. However, it places a greater emphasis on government oversight to control costs. Compared to fixed-price arrangements, CPFF may lead to higher overall costs if not managed diligently, but it allows for flexibility crucial in dynamic research environments.

What are the key performance indicators (KPIs) typically used to evaluate the success of clinical site monitoring contracts?

Key Performance Indicators (KPIs) for clinical site monitoring contracts are designed to ensure data integrity, regulatory compliance, and efficient trial progression. Common KPIs include the timeliness of site visits and monitoring report submissions, the number and severity of protocol deviations identified, the accuracy and completeness of source data verification, and the resolution rate of identified issues or action items. Other critical metrics might involve adherence to budget, timely identification of potential risks or safety concerns, and the overall quality of data generated from the monitored sites. The government contracting officer and technical representatives would typically establish specific, measurable, achievable, relevant, and time-bound (SMART) KPIs within the contract's Statement of Work (SOW). Evaluating the contractor's performance against these KPIs is essential for ensuring the scientific validity and regulatory acceptability of the research being conducted.

What is the track record of PPD Development LP in managing large federal contracts for research support?

PPD Development LP, now part of Thermo Fisher Scientific, has a significant track record in managing large-scale clinical research and development contracts, including those with federal agencies. As a major contract research organization (CRO), they have extensive experience in supporting pharmaceutical, biotechnology, and government-sponsored clinical trials across various therapeutic areas. Their federal contract history likely includes numerous awards from agencies like the NIH, the Department of Defense, and others, covering services such as clinical trial management, data analysis, regulatory affairs, and site monitoring. Evaluating their specific track record on federal contracts would involve reviewing past performance evaluations, any documented disputes or contract terminations, and the overall success of the programs they have supported. Generally, established CROs like PPD are selected for large contracts due to their demonstrated capabilities, infrastructure, and experience in navigating complex regulatory environments and managing large, geographically dispersed research projects.

How does the geographic location of North Carolina (sn: NORTH CAROLINA) influence the contract's execution or oversight?

The mention of North Carolina (sn: NORTH CAROLINA) likely refers to the location of PPD Development LP's operations or a significant operational hub relevant to this contract. North Carolina, particularly the Research Triangle Park area, is a major hub for the life sciences and pharmaceutical industries, hosting numerous biotech companies, research institutions, and CROs. Having a strong presence in such a location can facilitate access to a skilled workforce, foster collaborations, and potentially streamline operations for clinical research activities. For contract execution, it means PPD has established infrastructure and personnel in a region conducive to this type of work. From an oversight perspective, the government contracting officer would ensure that PPD's operations, regardless of location, meet all contractual requirements. While the physical location itself doesn't inherently change oversight mechanisms, a concentration of industry activity in North Carolina might imply a robust ecosystem for supporting such contracts efficiently.

What are the potential risks associated with a Cost Plus Fixed Fee contract for clinical site monitoring?

Cost Plus Fixed Fee (CPFF) contracts, while offering flexibility, carry inherent risks, particularly for the government. One primary risk is the potential for cost overruns if the contractor's costs exceed initial estimates, although the fixed fee limits the contractor's profit. This necessitates robust government oversight to scrutinize all claimed costs, ensuring they are reasonable, allocable, and allowable according to contract terms. There's also a risk that the contractor might be less incentivized to control costs aggressively compared to a fixed-price contract, as cost overruns are generally reimbursed. Furthermore, defining the scope of work and the fixed fee accurately from the outset can be challenging in complex R&D or service contracts, potentially leading to disputes over what is included in the fee versus reimbursable costs. Effective management requires clear communication, detailed reporting, and proactive identification and mitigation of risks throughout the contract's lifecycle.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: NIAIDDAIDSNIHAI2015045

Offers Received: 4

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 929 N FRONT ST, WILMINGTON, NC, 28401

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $139,861,060

Exercised Options: $135,144,719

Current Obligation: $135,144,719

Actual Outlays: $53,528,031

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline